Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences with a maintained price target of $52.
September 12, 2024 | 10:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences, maintaining a price target of $52. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $52 price target by Needham suggests positive sentiment and confidence in Harmony Biosciences' future performance. This is likely to have a positive short-term impact on the stock price as it may attract more investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100